BLS sees potential FY27 ‘upside’ as UK facility nears launch by Adam Sheldon September 8, 2026September 9, 2026 BLS Pharmaceuticals has flagged a potential increase to its FY27 revenue guidance, revealing its forecast of […]
Project Twenty21 Australia finds year-long improvements in pain and anxiety by Adam Sheldon September 7, 2026September 24, 2026
Déjà vu for ODC as inflated forecasts risk tying up national cannabis quota by Steve Jones September 3, 2026September 3, 2026
‘Inadequate and opportunistic’: Aurora formally rejects takeover bid by Steve Jones September 3, 2026September 3, 2026
Elixinol cuts H1 loss and announces deal to sell US hemp business by Adam Sheldon September 2, 2026September 3, 2026
Pastilles overtake flower as most prescribed dosage form for women by Steve Jones September 2, 2026September 2, 2026
Members sought for new group to ‘identify and respond’ to regulatory issues by Steve Jones September 1, 2026September 2, 2026
Argent BioPharma halves losses but faces funding ‘uncertainty’ by Adam Sheldon September 1, 2026September 3, 2026
Cann Group entering FY27 with ‘real momentum’, chairman says after year of financial juggling by Steve Jones August 31, 2026August 31, 2026
